Application of PD-1 pathway blockage in the treatment of colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2023.01.010

Abstract

Abstract:

Colorectal cancer is the second common cause of cancer death. Immunotherapy has became a new therapy apart from traditional therapy such as surgery,etc. There are controversial about the efficiency and adverse reaction of anti-PD-1/PD-L1 drugs. In this article, the research and application of PD-1 pathway blockage are reviewed from the aspects of PD-1 pathway and blockage, clinical applications of anti-PD-1/PD-L1 drugs in colorectal cancer, treatment resistance, adverse reactions and biomarkers of effective prediction.

Key words: Colorectal neoplasms, Immune checkpoint inhibitor, Treatment resistance, Adverse reaction, Biomarker

Jingfang Lv, Haiyang Huang, Enrui Liu, Meng Zhuang, Xishan Wang. Application of PD-1 pathway blockage in the treatment of colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2023, 12(01): 70-74.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2023.01.010

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2023/V12/I01/70

References 53

[1]	Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point[J]. Nature, 2017, 541(7637): 321-330.
[2]	Pardoll D. Cancer and the immune system: basic concepts and targets for intervention[J]. Seminars in Oncology, 2015, 42(4): 523-538.
[3]	Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor[J]. Immunity, 1999, 11(2): 141-151.
[4]	Okazaki T, Tanaka Y, Nishio R, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice[J]. Nature Medicine, 2003, 9(12): 1477-1483.
[5]	Iwai Y, Ishida M, Tanaka Y, et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade[J]. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99(19): 12293-12297.
[6]	Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J]. Nature Medicine, 2002, 8(8): 793-800.
[7]	Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes[J]. International Immunology, 1996, 8(5): 765-772.
[8]	Curiel TJ, Wei S, Dong H, et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity[J]. Nature Medicine, 2003, 9(5): 562-567.
[9]	Liu Y, Cheng Y, Xu Y, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers[J]. Oncogene, 2017, 36(44): 6143-6153.
[10]	Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2010, 28(19): 3167-3175.
[11]	Lipson EJ, Sharfman WH, Drake CG, et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody[J]. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2013, 19(2): 462-468.
[12]	Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. The New England Journal of Medicine, 2012, 366(26): 2443-2454.
[13]	Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study[J]. The Lancet Oncology, 2017, 18(9): 1182-1191.
[14]	Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2018, 36(8): 773-779.
[15]	Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers[J]. Nature Medicine, 2020, 26(4): 566-576.
[16]	Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors[J]. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2015, 21(19): 4286-4293.
[17]	O'Neil BH, Wallmark JM, Lorente D, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma[J]. PloS One, 2017, 12(12): e0189848.
[18]	Le DT, Kim TW, Van Cutsem E, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2020, 38(1): 11-19.
[19]	Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. The New England Journal of Medicine, 2015, 372(26): 2509-2520.
[20]	Rudek MA, Graham RA, Ratain MJ. Harmonization of renal function assessment is needed during early clinical development of oncology drugs[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2016, 34(2): 103-104.
[21]	Diaz LAJr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study[J]. Lancet Oncol, 2022, 23(5): 659-670.
[22]	Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients[J]. Nature, 2014, 515(7528): 563-567.
[23]	Hellmann MD, Kim TW, Lee CB, et al. Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors[J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2019, 30(7): 1134-1142.
[24]	Bendell J, Clardiello F, Tabernero J, et al. Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer[J]. Annals of Oncology, 2018, 29(suppl_5): v123.
[25]	Bendell JC, Powderly JD, Lieu CH, et al. Safety and efficacy of MPDL3280A (Suppl. 3) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC)[J]. Journal of Clinical Oncology, 2015, 33(suppl. 3): 704-704.
[26]	Segal NH, Saro J, Melero I, et al. Tabernero: phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC)[J]. Annals of Oncology, 2017, 28(Suppl. 5): v134.
[27]	Levy A, Massard C, Soria JC, et al. Concurrent irradiation with the anti-programmed cell death ligand-1 immune checkpoint blocker durvalumab: Single centre subset analysis from a phase 1/2 trial[J]. European Journal of Cancer (Oxford, England: 1990), 2016, 68: 156-162.
[28]	Wang C, Park J, Ouyang C, et al. A pilot feasibility study of yttrium-90 liver radioembolization followed by durvalumab and tremelimumab in patients with microsatellite stable colorectal cancer liver metastases[J]. The Oncologist, 2020, 25(5): 382-e776.
[29]	Filatenkov A, Baker J, Mueller AM, et al. Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions[J]. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2015, 21(16): 3727-3739.
[30]	Taylor K, Loo Yau H, Chakravarthy A, et al. An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors[J]. Journal for Immunotherapy of Cancer, 2020, 8(2): e000883.
[31]	Chen EX, Jonker DJ, Loree JM, et al. Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the canadian cancer trials group Co.26 study[J].JAMA Oncology, 2020, 6(6): 831-838.
[32]	Kim JH, Kim SY, Baek JY, et al. A phase Ⅱ study of avelumab monotherapy in patients with mismatch repair-deficient/microsatellite instability-high or POLE-mutated metastatic or unresectable colorectal cancer[J]. Cancer Research and Treatment: Official Journal of Korean Cancer Association, 2020, 52(4): 1135-1144.
[33]	Park SS, Dong H, Liu X, et al. PD-1 restrains radiotherapy-induced abscopal effect[J]. Cancer Immunology Research, 2015, 3(6): 610-619.
[34]	Woller N, Gürlevik E, Fleischmann-Mundt B, et al. Viral infection of tumors overcomes resistance to PD-1-immunotherapy by broadening neoantigenome-directed T-cell responses[J]. Molecular Therapy: the Journal of the American Society of Gene Therapy, 2015, 23(10): 1630-1640.
[35]	Sharma KK, Kalyani IH, Mohapatra J, et al. Evaluation of the oncolytic potential of R(2)B Mukteshwar vaccine strain of Newcastle disease virus (NDV) in a colon cancer cell line (SW-620)[J]. Archives of Virology, 2017, 162(9): 2705-2713.
[36]	Emens LA. Cancer vaccines: on the threshold of success[J]. Expert Opinion on Emerging Drugs, 2008, 13(2): 295-308.
[37]	Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer[J]. Nature, 2013, 500(7463): 415-421.
[38]	Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome[J]. Science (New York, NY) 2006, 313(5795): 1960-1964.
[39]	Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints[J]. Cancer Discovery, 2015, 5(1): 43-51.
[40]	Iwai Y, Hamanishi J, Chamoto K, et al. Cancer immunotherapies targeting the PD-1 signaling pathway[J]. Journal of Biomedical Science, 2017, 24(1): 26.
[41]	Wang PF, Chen Y, Song SY, et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis[J]. Frontiers in Pharmacology, 2017, 18(8): 730.
[42]	Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer--response[J]. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2013, 19(19): 5542.
[43]	Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review[J]. JAMA Oncology, 2016, 2(10): 1346-1353.
[44]	Baretti M, Le DT. DNA mismatch repair in cancer[J]. Pharmacology & Therapeutics, 2018, 189: 45-62.
[45]	Cabel L, Riva F, Servois V, et al. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study[J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2017, 28(8): 1996-2001.
[46]	Schmetterer KG, Pickl WF. The IL-10/STAT3 axis: Contributions to immune tolerance by thymus and peripherally derived regulatory T-cells[J]. European Journal of Immunology, 2017, 47(8): 1256-1265.
[47]	Ibáñez-Vea M, Zuazo M, Gato M, et al. Myeloid-derived suppressor cells in the tumor microenvironment: current knowledge and future perspectives[J]. Arch Immunol Ther Exp (Warsz), 2018, 66(2): 113-123.
[48]	Viaud S, Saccheri F, Mignot G, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide[J]. Science (New York, NY), 2013, 342(6161): 971-976.
[49]	Iida N, Dzutsev A, Stewart CA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment[J]. Science(New York, NY), 2013, 342(6161): 967-970.
[50]	Wang H, Yao H, Li C, et al. PD-L2 expression in colorectal cancer: Independent prognostic effect and targetability by deglycosylation[J]. Oncoimmunology, 2017, 6(7): e1327494.
[51]	Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy[J]. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research, 2014, 20(19): 5064-5074.
[52]	Danilova L, Wang H, Sunshine J, et al. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors[J]. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113(48): E7769-E7777.
[53]	Ahmad SM, Martinenaite E, Holmström M, et al. The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy[J]. Oncoimmunology, 2018, 7(2): e1390641.

Please choose a citation manager

Content to export